WHO restarts trial of COVID-19 drug hydroxychloroquineThe World Health Organization has restarted its trial of COVID-19 drug hydroxychloroquine, the malaria drug favoured by president Donald Trump, after a temporary Share XWHO restarts trial of COVID-19 drug hydroxychloroquinehttps://pharmaphorum.com/news/who-restarts-trial-of-covid-19-drug-hydroxychloroquine/
Gilead’s remdesivir could be $7.7bn blockbuster – analystAn influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying Share XGilead’s remdesivir could be $7.7bn blockbuster – analysthttps://pharmaphorum.com/news/gileads-remdesivir-could-be-7-7bn-blockbuster-analyst/
FDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’Roche has been given a green light by the FDA to use one of its diagnostic tests to Share XFDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’https://pharmaphorum.com/news/fda-clears-emergency-use-of-roche-test-for-covid-19-cytokine-storm/
COVID-19 driving adoption of virtual trialsA survey of clinical research professionals has found an acceleration in the adoption of virtual studies during the Share XCOVID-19 driving adoption of virtual trialshttps://pharmaphorum.com/news/covid-19-driving-adoption-of-virtual-trials/
AZ to work with Accent on RNA-modifying protein tech in cancerAstraZeneca is to work with US biotech Accent Therapeutics on therapies targeting RNA-modifying proteins (RMPs) for treatment of cancer. Share XAZ to work with Accent on RNA-modifying protein tech in cancerhttps://pharmaphorum.com/news/az-to-work-with-accent-on-rna-modifying-protein-tech-in-cancer/
Healthware Group acquires pharmaphorumHealthware Group has acquired pharmaphorum in a move that will combine its consulting and full-service agency capabilities with Share XHealthware Group acquires pharmaphorumhttps://pharmaphorum.com/digital/healthware-group-acquires-pharmaphorum/
NodThera raises $55m in Series B round to trial inflammatory disease drugsThe Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory Share XNodThera raises $55m in Series B round to trial inflammatory disease drugshttps://pharmaphorum.com/news/nodthera-raises/
Sanofi’s multiple myeloma drug approved in EUSanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Share XSanofi’s multiple myeloma drug approved in EUhttps://pharmaphorum.com/news/sanofis-multiple-myeloma-drug-approved-in-eu/
Digital triage tool eConsult is added to NHS appGP consultation tool eConsult is now available through the NHS app, extending the range of surgeries that can Share XDigital triage tool eConsult is added to NHS apphttps://pharmaphorum.com/news/digital-triage-tool-econsult-is-added-to-nhs-app/
